000167360 001__ 167360
000167360 005__ 20240229133538.0
000167360 0247_ $$2doi$$a10.1007/s00259-021-05189-3
000167360 0247_ $$2pmid$$apmid:33543325
000167360 0247_ $$2ISSN$$a0340-6997
000167360 0247_ $$2ISSN$$a1432-105X
000167360 0247_ $$2ISSN$$a1619-7070
000167360 0247_ $$2ISSN$$a1619-7089
000167360 0247_ $$2altmetric$$aaltmetric:99605181
000167360 037__ $$aDKFZ-2021-00306
000167360 041__ $$aeng
000167360 082__ $$a610
000167360 1001_ $$aAfshar-Oromieh, Ali$$b0
000167360 245__ $$aPerformance of [68Ga]Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer after prostatectomy-a multi-centre evaluation of 2533 patients.
000167360 260__ $$aHeidelberg [u.a.]$$bSpringer-Verl.$$c2021
000167360 3367_ $$2DRIVER$$aarticle
000167360 3367_ $$2DataCite$$aOutput Types/Journal article
000167360 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1626252002_15981
000167360 3367_ $$2BibTeX$$aARTICLE
000167360 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000167360 3367_ $$00$$2EndNote$$aJournal Article
000167360 500__ $$a#EA:E060#LA:C060# / 2021 Aug;48(9):2925-2934
000167360 520__ $$aTo evaluate the performance of [68Ga]Ga-PSMA-11 PET/CT in the diagnosis of recurrent prostate cancer (PC) after prostatectomy in a large multicentre cohort.The centres, which contributed to this study, were the departments of nuclear medicine of Heidelberg (Germany), Technical University of Munich (Germany) and Albert Einstein Hospital of São Paulo (Brazil). A total of 2533 patients who were scanned with [68Ga]Ga-PSMA-11 PET/CT at 1 h p.i. due to recurrent PC after prostatectomy were included in this retrospective analysis. Exclusion criteria were as follows: patients with untreated primary tumour, previous chemotherapy or Xofigo®; those previously treated with exclusively external beam radiation therapy or HIFU; those referred for PSMA-therapy; and those treated with ADT (including first- and second-generation ADT) within the last 6 months. Potential influences of different factors such as PSA level, PSA doubling-time (PSADT), PSA velocity (PSAVel), Gleason Score (GSC, including the separate analysis of 7a and 7b), age and amount of injected tracer were evaluated in a multivariable analysis.The rate of pathologic PET/CT-scans was 43% for PSA ≤ 0.2 ng/ml, 58% for PSA > 0.2 to ≤ 0.5, 72% for PSA > 0.5 to ≤ 1.0 and increased to a maximum of 93% for PSA > 10 ng/ml. A pathological PET/CT was significantly (p = 0.001) associated with PSA level and higher GSC. Amount of injected tracer, age, PSADT and PSAVel were not associated with a higher probability of a pathological scan.[68Ga]Ga-PSMA-11 PET/CT at 1 h p.i. confirmed its high performance in the largest patient cohort yet analysed. Tumour detection showed a clear association with higher PSA and higher GSC. No association was found between a pathological [68Ga]Ga-PSMA-11 PET/CT and age, amount of injected tracer, PSADT or PSAVel.
000167360 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000167360 588__ $$aDataset connected to CrossRef, PubMed,
000167360 650_7 $$2Other$$aPET/CT
000167360 650_7 $$2Other$$aPSMA
000167360 650_7 $$2Other$$aPositron emission tomography
000167360 650_7 $$2Other$$aProstate cancer
000167360 650_7 $$2Other$$aProstate-specific membrane antigen
000167360 7001_ $$ada Cunha, Marcelo Livorsi$$b1
000167360 7001_ $$aWagner, Jairo$$b2
000167360 7001_ $$0P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aHaberkorn, Uwe$$b3$$udkfz
000167360 7001_ $$aDebus, Nils$$b4
000167360 7001_ $$aWeber, Wolfgang$$b5
000167360 7001_ $$aEiber, Matthias$$b6
000167360 7001_ $$0P:(DE-He78)457c042884c901eb0a02c18bb1d30103$$aHolland-Letz, Tim$$b7$$eLast author$$udkfz
000167360 7001_ $$aRauscher, Isabel$$b8
000167360 773__ $$0PERI:(DE-600)2098375-X$$a10.1007/s00259-021-05189-3$$n9$$p2925-2934$$tEuropean journal of nuclear medicine and molecular imaging$$v48$$x1619-7089$$y2021
000167360 909CO $$ooai:inrepo02.dkfz.de:167360$$pVDB
000167360 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000167360 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)457c042884c901eb0a02c18bb1d30103$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000167360 9130_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000167360 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000167360 9141_ $$y2021
000167360 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2020-08-29$$wger
000167360 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-08-29
000167360 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-08-29
000167360 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-08-29
000167360 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-08-29
000167360 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-08-29
000167360 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2020-08-29
000167360 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-08-29
000167360 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-08-29
000167360 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-08-29
000167360 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-08-29
000167360 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J NUCL MED MOL I : 2018$$d2020-08-29
000167360 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J NUCL MED MOL I : 2018$$d2020-08-29
000167360 9201_ $$0I:(DE-He78)E060-20160331$$kE060$$lE060 KKE Nuklearmedizin$$x0
000167360 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x1
000167360 980__ $$ajournal
000167360 980__ $$aVDB
000167360 980__ $$aI:(DE-He78)E060-20160331
000167360 980__ $$aI:(DE-He78)C060-20160331
000167360 980__ $$aUNRESTRICTED